FVR Suomen rokotetutkimus Oy
- Address
- Lemminkaisenkatu 14-18 B, 20520 Turku, Finland
Bacterial Infections and Mycoses
The Turun Rokotetutkimusklinikka conducts studies aimed at preventing pneumococcal infections through novel vaccine candidates, focusing on safety and immune response in young children.
- Safety assessment of a conjugate vaccine in toddlers
- Immunogenicity profiling after a two‑dose schedule
- Evaluation of antibody seroconversion against bacterial pathogens
These efforts complement the site’s broader work on respiratory diseases and are coordinated by FVR Suomen rokotetutkimus Oy.
Respiratory Tract Diseases
Research at the clinic includes trials to reduce the burden of influenza virus and respiratory syncytial virus (RSV) in both seniors and infants, testing new vaccines and monoclonal antibodies for effectiveness and tolerability.
- Comparison of an adjuvanted influenza vaccine with standard options for adults over 65
- Evaluation of a next‑generation RSV vaccine in infants at high risk
- Head‑to‑head safety study of a new RSV monoclonal antibody versus palivizumab
The program aims to improve preventive care for vulnerable populations while advancing knowledge of respiratory immunity.
Virus Diseases
The site is also engaged in studies targeting broader virus diseases, including a comparative trial of an investigational yellow fever vaccine against an established reference product.
- Non‑inferiority assessment of antibody response to a new yellow fever vaccine
- Safety monitoring of viral vaccine candidates in healthy adults
- Immunogenicity evaluation across diverse viral antigens
These investigations support global efforts to strengthen viral disease prevention and are conducted alongside the clinic’s respiratory research.
Immune System Processes
Across all vaccine studies, the clinic measures key immune system processes such as seroconversion, cellular response, and tolerability to understand how new products stimulate protection.
- Seroconversion rates after administration of influenza and RSV vaccines
- Immune profiling of participants receiving bacterial conjugate vaccines
- Impact of adjuvants on the magnitude of the antibody response
This focus on immunological outcomes helps ensure that each trial not only proves efficacy but also clarifies how the body defends itself against infection.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Merck Sharp & Dohme LLC2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 107 other sites in Finland
Therapeutic Area Benchmark — Finland
Select a therapeutic area to compare against other sites in Finland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Finland
Market Share
Country: Finland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in FVR Suomen rokotetutkimus Oy
lock Showing 1 of 6 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2b/3 Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-1654 in Healthy Pre-Term and Full-Term Infants | Merck Sharp & Dohme LLC | Phase IV | Not Recruiting | Nov 2022 | Feb 2024 |
IMP list
lock Showing 1 of 13 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| 534 | 1 | Unknown | 2024-08-09 | 2024-08-09 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.